1. Home >
  2. M&A >
  3. Venture >
  4. United States >
  5. North Carolina >
  6. Eight Roads Invests In Precision BioSciences

Investment Summary

Eight Roads Invests In Precision BioSciences

On May 11, 2015, private equity firm Eight Roads invested in life science company Precision BioSciences

Investment Highlights
  • This is Eight Roads’ 30th transaction in the Life Science sector.
  • This is Eight Roads’ 47th transaction in the United States.
  • This is Eight Roads’ 2nd transaction in North Carolina.
Investment Fate
  • Precision BioSciences went public in 2019.

Investment Summary
Date 2015-05-11
Target Precision BioSciences
Sector Life Science
Investor(s) Eight Roads
Deal Type Venture

Target

Precision BioSciences

Durham, North Carolina, United States
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision BioSciences was founded in 2006 and is based in Durham, North Carolina.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Eight Roads

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1969
PE ASSETS 11.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

DEAL STATS #
Overall 104 of 293
Sector: Life Science M&A 30 of 73
Type: Venture M&A Deals 86 of 266
State: North Carolina M&A 2 of 2
Country: United States M&A 47 of 120
Year: 2015 M&A 16 of 25
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-06 Adaptimmune

Abingdon, United Kingdom

Adaptimmune is a clinical-stage biopharmaceutical company that focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide-enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. Adaptimmune was founded in 2008 and is based in Abingdon, England.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-15 Shanghai Hile Bio-Technology

Shanghai, China

Shanghai Hile Bio-Technology researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. Shanghai Hile Bio-Technology was founded in 1981 and is based in Shanghai, China.

Sell -
Mergr

Solution for

Product

Company

Legal